WA
ALXN

Wealth Alliance’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealth Alliance’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,177
Closed -$249K – 384
2020
Q3 		$249K Buy
2,177
+179
+9% +$19.3K 0.09% 276
2020
Q2 		$224K Buy
+1,998
New +$212K 0.09% 268

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wealth Alliance's ALXN Position: Q4 2020 in Review

Wealth Alliance sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 2,177 shares — an estimated $249K sold.

Wealth Alliance first reported a position in ALXN in Q2 2020 and held it in 2 quarters. The position peaked at $249K in Q3 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Wealth Alliance reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Wealth Alliance sold 2,177 Alexion Pharmaceuticals shares in Q4 2020, an estimated $249K.
  • Wealth Alliance first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Wealth Alliance's Alexion Pharmaceuticals position peaked at $249K in Q3 2020.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Wealth Alliance's 13F filing for Q4 2020, filed 11 Feb 2021.